DIA Biosimilars 2013

Xention

Xention, Servier collaborate for atrial fibrillation treatment

Wednesday, October 2, 2013 12:59 PM

Xention, a Cambridge-based biopharmaceutical company specializing in discovery and development of ion channel-modulating drugs for atrial fibrillation (AF), and Servier, an independent French pharmaceutical company, have entered  a multi-year agreement for  development and commercialization of XEN-D0103, a selective Kv1.5 modulator discovered and developed by Xention for the treatment of AF.

More... »

Cenduit: Now with Patient Reminders

Xention, Ono continue collaboration

Tuesday, April 12, 2011 11:21 AM

Xention, a Cambridge, U.K.-based biopharmaceutical company that discovers and develops ion channel-modulating drugs, will extend its collaboration with Ono Pharmaceutical.  The two-year agreement between the companies began in March 2009.  The collaboration has been successful in identifying multiple compounds that selectively modulate the function of target ion channels, and the two have agreed to extend the drug-discovery collaboration for another year.

More... »

CRF Health – eCOA Forum
CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.